Technology | 2019.12.03
Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has entered into a partnership with Ethicann Pharmaceuticals Inc. (“Ethicann”), a Calgary-based pharmaceutical company using botanically sourced cannabinoid oils to formulate prescription drugs. The program will initially focus on using Catalent’s proven Zydis® orally disintegrating tablet technology to develop a new combination pharmaceutical-grade cannabidiol (CBD) and tetrahydrocannabinol (THC) product that, if approved, would treat patients suffering from multiple sclerosis (MS) spasticity.
(PRWeb December 03, 2019)
Read the full story at https://www.prweb.com/releases/catalent_to_partner_with_ethicann_on_new_fast_dissolve_cannabinoid_based_treatment_for_multiple_sclerosis_spasticity/prweb16761233.htm
For more information, please visit
https://www.prweb.com/releases/catalent_[...]s_spasticity/prweb16761233.htm
Instagram is adding automatic in-app text translation - The Verge views: 1585
Instagram is adding automatic in-app text translation - The Verge views: 1508